How long does it take to take Capisetinib/Caposetinib to take effect?

Capivasertib is a small molecule inhibitor targeting the AKT signaling pathway. It is used in combination with Fulvestrant to treat patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with PIK3CA, AKT1 or PTEN gene alterations. This drug is mainly targeted at individuals who have developed resistance or disease progression during previous endocrine therapy. As a new direction for precision treatment, its clinical efficacy has attracted great attention.

Judging from clinical practice and overseas research experience, the onset of effect of capositinib is not immediately visible, but a more obvious therapeutic response can only be observed after several weeks of continuous use. Under normal circumstances, most patients begin to experience initial effects such as shrinkage of lesions, decrease in tumor indicators or relief of symptoms after taking it for about 4 to 8 weeks. Some patients with high levels of biomarker expression may respond faster to drugs, but there are individual differences.

The speed at which a drug takes effect is also affected by multiple factors, such as tumor burden, disease progression rate, target mutation type, and combination drug regimen. Capacetinib blocks the proliferation and survival signals of cancer cells by inhibiting the abnormal activation of thePI3K/AKT pathway. Therefore, its mechanism determines that it requires a sustained effect for a certain period of time to control tumor formation.

The synergistic effect of combined medication cannot be ignored. Fulvestrant, as an estrogen receptor down-regulator, can further inhibit the endocrine-dependent mechanism of tumors and synergize with capositinib to accelerate the response time of lesions. Most treatment plans will closely observe changes in the condition at the beginning of the treatment course, and conduct the first imaging evaluation at 6 to 8 weeks to determine whether to continue to maintain the plan.

It needs to be clear that capositinib is not a "quick-acting" drug. Its real value lies in the continuous control of tumor progression and delaying the occurrence of drug resistance. During the treatment process, patients should remain patient and take the medication in strict accordance with the doctor's instructions. They should not stop the medication or adjust the dose without authorization due to slow onset of effect.

Reference materials:https://www.drugs.com/mtm/capivasertib.html